Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Are You Buying Gilead Sciences, Inc. for the Wrong Reason?

TheMotleyFool

0 0

Are You Buying Gilead Sciences, Inc. for the Wrong Reason?

Gilead Sciences (NASDAQ: GILD) is up about 12% over the last week or so since Novartis (NYSE: NVS) got its chimeric antigen receptor T-cell (CAR-T) therapy Kymriah approved by the FDA.

That's just ridiculous for a couple of reasons:

The best-case scenario for Gilead wasn't an FDA approval of Kymriah, but a rejection based on some reason other than the fact that it was a CAR-T therapy.

Source: Fool.com